Molecular cloning, expression and characterization of ribokinase of Leishmania major.

Acta Biochim Biophys Sin (Shanghai)

Department of Medical Biochemistry, University of Nigeria, Enugu 1000004, Nigeria.

Published: June 2007

Ribokinase (EC 2.1.7.15) from Leishmania major was cloned, sequenced and overexpressed in Escherichia coli. The gene expressed an active enzyme that had comparable activity to the same enzyme studied in E. coli. It specifically phosphorylated D-ribose. Under defined conditions, the K(m) for the substrates D-ribose and ATP were 0.3+/-0.04 mM and 0.2+/-0.02 mM, respectively. The turnover numbers of the enzyme for the substrates were 10.8 s(-1) and 10.2 s(-1), respectively. The enzyme product ribose 5-phosphate inhibited the phosphorylation of D-ribose with an apparent K(i) of 0.4 mM, which is close to the K(m) (0.3 mM) of D-ribose, suggesting that it might play a role in regulating flux through the enzyme.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1745-7270.2007.00298.xDOI Listing

Publication Analysis

Top Keywords

leishmania major
8
enzyme
5
molecular cloning
4
cloning expression
4
expression characterization
4
characterization ribokinase
4
ribokinase leishmania
4
major ribokinase
4
ribokinase 21715
4
21715 leishmania
4

Similar Publications

Visceral leishmaniasis (VL) is a vector-borne disease caused by the obligate intracellular protozoan in India. VL can be complicated by post-kala-azar dermal leishmaniasis (PKDL), a macular or nodular rash that develops in 10%-20% of patients after treatment of VL in India. Patients with PKDL are infectious to sand flies, promoting further transmission of the parasite.

View Article and Find Full Text PDF

Identification of a New Pentafluorosulfanyl-Substituted Chalcone with Activity Against Hepatoma and Human Parasites.

Pharmaceuticals (Basel)

January 2025

Institute of Physiology, Charité-Universitätsmedizin Berlin, Corporate Member of the Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.

Background/objectives: New drugs are required for the treatment of liver cancers and protozoal parasite infections. Analogs of the known anticancer active and antileishmanial 2',4',6'-trimethoxychalcone SU086 were prepared and investigated.

Methods: The chalcones were prepared according to the Claisen-Schmidt condensation protocol and analyzed.

View Article and Find Full Text PDF

Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors.

Pharmaceuticals (Basel)

December 2024

Department of Biomedical Engineering, School of Engineering Sciences, College of Basic & Applied Sciences, University of Ghana, Legon, Accra P.O. Box LG 77, Ghana.

: Pteridine reductase 1 (PTR1) has been one of the prime targets for discovering novel antileishmanial therapeutics in the fight against Leishmaniasis. This enzyme catalyzes the NADPH-dependent reduction of pterins to their tetrahydro forms. While chemotherapy remains the primary treatment, its effectiveness is constrained by drug resistance, unfavorable side effects, and substantial associated costs.

View Article and Find Full Text PDF

The Potential Role of Sanguinarine as an Inhibitor of Leishmania PP2C in the Induction of Apoptosis.

Acta Parasitol

January 2025

División de Investigación, Facultad de Medicina, Unidad de Investigación UNAM-INC, Universidad Nacional Autónoma de México, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Col. Sección XVI, Ciudad de México, C.P. 14080, México.

Leishmania spp. cause a wide range of human diseases, localized skin lesions, mucocutaneous and visceral infections. In the present study, the aim was to investigate the potential role of sanguinarine as a specific inhibitor of Leishmania PP2C that can induce apoptosis in the parasite.

View Article and Find Full Text PDF

Leishmaniasis is a major public health problem, especially affecting vulnerable populations in tropical and subtropical regions. The disease is endemic in 90 countries, and with millions of people at risk, it is seen as one of the ten most neglected tropical diseases. Current treatments face challenges such as high toxicity, side effects, cost, and growing drug resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!